Was ist dran an QUESTCOR PHARMACEUTICALS INC? - 500 Beiträge pro Seite
eröffnet am 10.04.06 13:24:16 von
neuester Beitrag 30.12.08 18:14:35 von
neuester Beitrag 30.12.08 18:14:35 von
Beiträge: 48
ID: 1.053.131
ID: 1.053.131
Aufrufe heute: 0
Gesamt: 6.829
Gesamt: 6.829
Aktive User: 0
ISIN: US74835Y1010 · WKN: 899085
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 13,110 | +38,44 | |
| 1,1514 | +30,84 | |
| 0,9150 | +21,84 | |
| 1,2100 | +21,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,0300 | -19,90 | |
| 36,70 | -22,87 | |
| 2,5500 | -25,22 | |
| 1,3500 | -26,63 | |
| 2,7280 | -29,14 |
Feedback
Wer kann was zu QUESTCOR PHARMACEUTICALS INC. beitragen?
Also schon 75 Besucher hier und keinem fällt was ein
ich find auch nichts.
Moin,
nach größeren Stückzahlen von vielen Insiderkäufen vom Questcor-Vorstand (veröffentlicht in der EURO am Sonntag Oktober/November 05) bin ich aufmerksam auf diese Aktie geworden. Ich habe mich dann aufgrund der Umstrukturierung (Rückbesinnung auf das Kerngeschäft) und des niedrigen KGVs (10) im November 2005 für den Kauf entschieden.
Die Firma hat meiner Meinung nach aufgrund des Turnarounds weiter Potenzial und erwirtschaftet bereits Gewinne. Weiterhin wird Questcor mit sehr wenig Stückzahlen in Deutschland gehandelt, die Aktie ist somit noch nicht im Focus vieler Anleger.
Gegen einen Kauf von Questcor-Aktien spricht die Vergangenheit (schlechte Performance aufgrund falscher Firmenphilosophie).
Zusammengefaßt werde ich meine Stückzahlen weiter ausbauen und langfristig halten.
Goden Tach leeve Lüt,
Opafritzotto
nach größeren Stückzahlen von vielen Insiderkäufen vom Questcor-Vorstand (veröffentlicht in der EURO am Sonntag Oktober/November 05) bin ich aufmerksam auf diese Aktie geworden. Ich habe mich dann aufgrund der Umstrukturierung (Rückbesinnung auf das Kerngeschäft) und des niedrigen KGVs (10) im November 2005 für den Kauf entschieden.
Die Firma hat meiner Meinung nach aufgrund des Turnarounds weiter Potenzial und erwirtschaftet bereits Gewinne. Weiterhin wird Questcor mit sehr wenig Stückzahlen in Deutschland gehandelt, die Aktie ist somit noch nicht im Focus vieler Anleger.
Gegen einen Kauf von Questcor-Aktien spricht die Vergangenheit (schlechte Performance aufgrund falscher Firmenphilosophie).
Zusammengefaßt werde ich meine Stückzahlen weiter ausbauen und langfristig halten.
Goden Tach leeve Lüt,
Opafritzotto
Trading Spotlight
Antwort auf Beitrag Nr.: 21.167.645 von OpaFritzOtto am 11.04.06 22:07:39Nächste Woche kommen die Quartalszahlen. Bin gespannt ob wir ein neues High sehen werden.
http://news.morningstar.com/news/BW/M05/D04/20060504006256.h…
http://news.morningstar.com/news/BW/M05/D05/20060505005096.h…
http://news.morningstar.com/news/BW/M05/D04/20060504006256.h…
http://news.morningstar.com/news/BW/M05/D05/20060505005096.h…
Antwort auf Beitrag Nr.: 21.451.811 von fr1 am 05.05.06 23:03:55Gemach gemach!
Zum neuen High ist es noch ein gutes Stück!
Diese Aktie schimmelt in meinem Depot schon seit Jahren vor sich hin. Ich hatte sie schon als Depotleiche abgeschrieben...
Die letzten Quartalszahlen hatten mich schon überascht. Nach "ominösen" Umstrukturierungen nun plötzlich Zukäufe!? Weiß nicht so recht, wie das zu deuten ist. Scheint aber in die richtige Richtung zu gehen!
Charttechnisch jedenfalls ein klarer Kauf! Sieht USA offensichtlich auch so und dort spielt die Musik!
Mal schaun, was der Dienstag so bringt. Bin jedenfalls mächtig gespannt...
Gruß an alle die durchgehalten haben!
rohbi
Zum neuen High ist es noch ein gutes Stück!
Diese Aktie schimmelt in meinem Depot schon seit Jahren vor sich hin. Ich hatte sie schon als Depotleiche abgeschrieben...
Die letzten Quartalszahlen hatten mich schon überascht. Nach "ominösen" Umstrukturierungen nun plötzlich Zukäufe!? Weiß nicht so recht, wie das zu deuten ist. Scheint aber in die richtige Richtung zu gehen!
Charttechnisch jedenfalls ein klarer Kauf! Sieht USA offensichtlich auch so und dort spielt die Musik!
Mal schaun, was der Dienstag so bringt. Bin jedenfalls mächtig gespannt...
Gruß an alle die durchgehalten haben!
rohbi
Antwort auf Beitrag Nr.: 21.452.181 von rohbi am 06.05.06 00:03:54Moin,
vielleicht ist hier ja noch jemand in Questcor investiert? Ich habe mir gerade die Quartalsergebnisse für das 2. Ouartal durchgelesen. Ich bin zufrieden
.
Questcor Announces Financial Results for 2006 Second Quarter; Sales of Acthar Gel Exceed $3 Million; 60% Increase Over First Quarter 2006
UNION CITY, Calif.--(BUSINESS WIRE)--Aug. 8, 2006--Questcor Pharmaceuticals, Inc. (AMEX:QSC) today reported its financial results for the second quarter ended June 30, 2006. Total net product sales for the second quarter of 2006 were $3.3 million, up 66% from $2.0 million in the first quarter of 2006. Net loss applicable to common shareholders totaled $2.2 million, or $0.04 per share, for the second quarter of 2006, compared to net loss applicable to common shareholders of $3.0 million, or $0.06 per share, for the first quarter of 2006.
"Questcor is beginning to see the benefits from the significant effort and investment we have made over the past year to transform Questcor into a leading CNS focused specialty pharmaceutical company. This past quarter saw our recently expanded sales force begin to effectively communicate the compelling information that supports Acthar Gel's significant potential in the multiple sclerosis market. The prescription trends that we began to recognize late in the first quarter led to the 60% growth in Acthar sales over the first quarter of 2006 and we are pleased that these trends continue to be reflected in prescription trends this quarter," said James Fares, President and CEO of Questcor.
"With the successful completion of the acquisition of Doral(R) in May and the subsequent training of our proven 40-person sales team, we enter the third quarter with growing momentum across all areas of our business. In mid-July our sales force began actively promoting Doral for the first time, increasing the number of product presentations we make to physicians to over 7,000 per month. We expect this will allow us to continue to capitalize on the potential of both of our marketed products. We also remain focused on adding our first clinical program to our development pipeline. We are evaluating a number of products that would fit with our CNS focus, could be developed at a comparatively low cost with reduced clinical risk, and complement our marketed products," he continued.
Financial Results for the Three and Six Month Periods Ended June 30, 2006
As of June 30, 2006, Questcor's cash, cash equivalents and short-term investments totaled $11.4 million and working capital totaled $9.8 million. In May 2006, Questcor made an upfront payment of $2.5 million to acquire Doral. Questcor will make an additional payment of $1.5 million after the approval of the new manufacturer of the Doral active pharmaceutical ingredient.
Total net product sales were $3.3 million and $5.3 million for the three and six month periods ended June 30, 2006, respectively, of which net product sales of Acthar were $3.2 million and $5.2 million, respectively. Questcor began selling Doral in late May, but did not begin promoting the product until mid-July. Operating costs and expenses were $5.7 million and $10.9 million for the three and six month periods ended June 30, 2006, respectively, of which selling, general and administrative expenses were $4.2 million and $8.4 million, respectively. In the first quarter of 2006, Questcor completed an expansion of its sales team to 40 sales representatives and sales management personnel.
As of June 30, 2006, Questcor had 56,829,974 common shares outstanding. During the three month period ended June 30, 2006, 1,986,444 shares of common stock were issued, resulting primarily from the issuance of 1,647,440 shares of common stock upon the net exercise of 2,889,925 warrants.
Questcor's results for the three and six month periods ended June 30, 2006 are not directly comparable to the corresponding periods in 2005 due to significant changes to Questcor's business in 2006 and 2005. These changes primarily included the sale of Questcor's non-core products Nascobal(R), Ethamolin(R) and Glofil(R)-125 and the retirement of Questcor's outstanding debt and convertible debentures in 2005, the elimination of Questcor's Series B preferred stock and the expansion of Questcor's sales force in the first quarter of 2006, and Questcor's acquisition of Doral in the second quarter of 2006.
Quarter Ended June 30, 2006 Conference Call -- Questcor will be hosting a conference call to discuss these results on Tuesday, August 8, 2006 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Please call the following numbers to participate: (800) 741-6056 (domestic) or (706) 679-3280 (international) and use conference ID number 3705863. Participants are asked to call the above numbers 5-10 minutes prior to the starting time.
This call is being webcast by Thomson/CCBN and can be accessed at Questcor's website at www.questcor.com. The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at www.earnings.com, Thomson/CCBN's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents (www.streetevents.com).
A telephonic replay of this call will be available from 9:00 p.m. Eastern Time on Tuesday, August 8, 2006 through 11:59 p.m. Eastern Time on Tuesday, August 15, 2006. Please call (800) 642-1687 (domestic) or (706) 645-9291 (international) and use conference ID number 3705863.
About Questcor -- Questcor Pharmaceuticals, Inc.(R) (AMEX:QSC) is a specialty pharmaceutical company that develops and commercializes novel therapeutics for the treatment of neurological disorders. Questcor currently markets H.P. Acthar(R) Gel (repository corticotropin injection), an injectable drug indicated for the treatment of exacerbations associated with Multiple Sclerosis and Doral(R) (quazepam) that is indicated for the treatment of insomnia, characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.
Note: Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Such statements are subject to certain factors, which may cause Questcor's results to differ from those reported herein. Factors that may cause such differences include, but are not limited to, Questcor's ability to accurately forecast and create the demand for its products, the gross margin achieved from the sale of its products, Questcor's ability to enforce its product returns policy, the accuracy of the prescription data purchased from independent third parties by Questcor, the sell-through by Questcor's distributors, the inventories carried by Questcor's distributors, and the expenses and other cash needs for the upcoming periods, Questcor's ability to obtain finished goods from its sole source contract manufacturers on a timely basis if at all, Questcor's potential future need for additional funding, Questcor's ability to utilize its net operating loss carry forwards to reduce income taxes on the sale of its non-core products, uncertainties regarding Questcor's intellectual property and other research, development, marketing and regulatory risks, and to the ability of Questcor to implement its strategy and acquire products and, if acquired, to market them successfully as well as the risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2005 and other documents filed with the Securities and Exchange Commission. The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.
Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Auf jeden Fall sind wir wieder in der Gewinnzone..............
Viele Grüße,
Opafritzotto
vielleicht ist hier ja noch jemand in Questcor investiert? Ich habe mir gerade die Quartalsergebnisse für das 2. Ouartal durchgelesen. Ich bin zufrieden
.Questcor Announces Financial Results for 2006 Second Quarter; Sales of Acthar Gel Exceed $3 Million; 60% Increase Over First Quarter 2006
UNION CITY, Calif.--(BUSINESS WIRE)--Aug. 8, 2006--Questcor Pharmaceuticals, Inc. (AMEX:QSC) today reported its financial results for the second quarter ended June 30, 2006. Total net product sales for the second quarter of 2006 were $3.3 million, up 66% from $2.0 million in the first quarter of 2006. Net loss applicable to common shareholders totaled $2.2 million, or $0.04 per share, for the second quarter of 2006, compared to net loss applicable to common shareholders of $3.0 million, or $0.06 per share, for the first quarter of 2006.
"Questcor is beginning to see the benefits from the significant effort and investment we have made over the past year to transform Questcor into a leading CNS focused specialty pharmaceutical company. This past quarter saw our recently expanded sales force begin to effectively communicate the compelling information that supports Acthar Gel's significant potential in the multiple sclerosis market. The prescription trends that we began to recognize late in the first quarter led to the 60% growth in Acthar sales over the first quarter of 2006 and we are pleased that these trends continue to be reflected in prescription trends this quarter," said James Fares, President and CEO of Questcor.
"With the successful completion of the acquisition of Doral(R) in May and the subsequent training of our proven 40-person sales team, we enter the third quarter with growing momentum across all areas of our business. In mid-July our sales force began actively promoting Doral for the first time, increasing the number of product presentations we make to physicians to over 7,000 per month. We expect this will allow us to continue to capitalize on the potential of both of our marketed products. We also remain focused on adding our first clinical program to our development pipeline. We are evaluating a number of products that would fit with our CNS focus, could be developed at a comparatively low cost with reduced clinical risk, and complement our marketed products," he continued.
Financial Results for the Three and Six Month Periods Ended June 30, 2006
As of June 30, 2006, Questcor's cash, cash equivalents and short-term investments totaled $11.4 million and working capital totaled $9.8 million. In May 2006, Questcor made an upfront payment of $2.5 million to acquire Doral. Questcor will make an additional payment of $1.5 million after the approval of the new manufacturer of the Doral active pharmaceutical ingredient.
Total net product sales were $3.3 million and $5.3 million for the three and six month periods ended June 30, 2006, respectively, of which net product sales of Acthar were $3.2 million and $5.2 million, respectively. Questcor began selling Doral in late May, but did not begin promoting the product until mid-July. Operating costs and expenses were $5.7 million and $10.9 million for the three and six month periods ended June 30, 2006, respectively, of which selling, general and administrative expenses were $4.2 million and $8.4 million, respectively. In the first quarter of 2006, Questcor completed an expansion of its sales team to 40 sales representatives and sales management personnel.
As of June 30, 2006, Questcor had 56,829,974 common shares outstanding. During the three month period ended June 30, 2006, 1,986,444 shares of common stock were issued, resulting primarily from the issuance of 1,647,440 shares of common stock upon the net exercise of 2,889,925 warrants.
Questcor's results for the three and six month periods ended June 30, 2006 are not directly comparable to the corresponding periods in 2005 due to significant changes to Questcor's business in 2006 and 2005. These changes primarily included the sale of Questcor's non-core products Nascobal(R), Ethamolin(R) and Glofil(R)-125 and the retirement of Questcor's outstanding debt and convertible debentures in 2005, the elimination of Questcor's Series B preferred stock and the expansion of Questcor's sales force in the first quarter of 2006, and Questcor's acquisition of Doral in the second quarter of 2006.
Quarter Ended June 30, 2006 Conference Call -- Questcor will be hosting a conference call to discuss these results on Tuesday, August 8, 2006 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Please call the following numbers to participate: (800) 741-6056 (domestic) or (706) 679-3280 (international) and use conference ID number 3705863. Participants are asked to call the above numbers 5-10 minutes prior to the starting time.
This call is being webcast by Thomson/CCBN and can be accessed at Questcor's website at www.questcor.com. The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at www.earnings.com, Thomson/CCBN's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents (www.streetevents.com).
A telephonic replay of this call will be available from 9:00 p.m. Eastern Time on Tuesday, August 8, 2006 through 11:59 p.m. Eastern Time on Tuesday, August 15, 2006. Please call (800) 642-1687 (domestic) or (706) 645-9291 (international) and use conference ID number 3705863.
About Questcor -- Questcor Pharmaceuticals, Inc.(R) (AMEX:QSC) is a specialty pharmaceutical company that develops and commercializes novel therapeutics for the treatment of neurological disorders. Questcor currently markets H.P. Acthar(R) Gel (repository corticotropin injection), an injectable drug indicated for the treatment of exacerbations associated with Multiple Sclerosis and Doral(R) (quazepam) that is indicated for the treatment of insomnia, characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.
Note: Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Such statements are subject to certain factors, which may cause Questcor's results to differ from those reported herein. Factors that may cause such differences include, but are not limited to, Questcor's ability to accurately forecast and create the demand for its products, the gross margin achieved from the sale of its products, Questcor's ability to enforce its product returns policy, the accuracy of the prescription data purchased from independent third parties by Questcor, the sell-through by Questcor's distributors, the inventories carried by Questcor's distributors, and the expenses and other cash needs for the upcoming periods, Questcor's ability to obtain finished goods from its sole source contract manufacturers on a timely basis if at all, Questcor's potential future need for additional funding, Questcor's ability to utilize its net operating loss carry forwards to reduce income taxes on the sale of its non-core products, uncertainties regarding Questcor's intellectual property and other research, development, marketing and regulatory risks, and to the ability of Questcor to implement its strategy and acquire products and, if acquired, to market them successfully as well as the risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2005 and other documents filed with the Securities and Exchange Commission. The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.
Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Auf jeden Fall sind wir wieder in der Gewinnzone..............
Viele Grüße,
Opafritzotto
Antwort auf Beitrag Nr.: 23.361.612 von OpaFritzOtto am 08.08.06 22:46:55Moin,
ich bin noch dabei und so schlecht schaut's tatsächlich nicht aus!
Von der Gewinnzone ist QSC schon noch ein Stück entfernt aber immerhin geht's in die richtige Richtung. Offensichtlich kommt das Geschäft in Schwung und es wird Geld verdient.
Zufrieden bin ich soweit auch mit den Ergebnissen, die waren aber so erwartet. Deshalb geht's auch mit dem Kurs (und den Umsätzen) relativ stabil weiter. Ist nicht verkehrt, denn das hatten wir auch schon anders...
Gruß
rohbi
ich bin noch dabei und so schlecht schaut's tatsächlich nicht aus!
Von der Gewinnzone ist QSC schon noch ein Stück entfernt aber immerhin geht's in die richtige Richtung. Offensichtlich kommt das Geschäft in Schwung und es wird Geld verdient.
Zufrieden bin ich soweit auch mit den Ergebnissen, die waren aber so erwartet. Deshalb geht's auch mit dem Kurs (und den Umsätzen) relativ stabil weiter. Ist nicht verkehrt, denn das hatten wir auch schon anders...
Gruß
rohbi
Ja was sagt man denn dazu...
New Questcor drug to be reviewed by FDA
Wednesday August 23, 5:38 pm ET
Questcor Pharmaceuticals Inc. said Wednesday the U.S. Food and Drug Administration has accepted for review the company's supplemental new drug application for treatment of infantile spasms.
Union City-based Questcor (AMEX:QSC - News) said the FDA is expected make a decision during the second quarter of 2007. No drug is currently approved in the United States for the treatment of infantile spasms, Questcor said.
Infantile spasm is a seizure disorder of early childhood also known as West Syndrome. Typically, the child suffers a sudden bending forward and stiffening of the body, arms, and legs; there can also be arching of the torso. The spasms may be connected with later conditions such as cerebral palsy, epilepsy, and mental retardation.
Published August 23, 2006 by the Silicon Valley/San Jose Business Journal
Ausführlichere Infos gibt's hier:
http://phx.corporate-ir.net/phoenix.zhtml?c=89528&p=irol-new…
Werde ich womöglich doch noch reich?
Gruß
New Questcor drug to be reviewed by FDA
Wednesday August 23, 5:38 pm ET
Questcor Pharmaceuticals Inc. said Wednesday the U.S. Food and Drug Administration has accepted for review the company's supplemental new drug application for treatment of infantile spasms.
Union City-based Questcor (AMEX:QSC - News) said the FDA is expected make a decision during the second quarter of 2007. No drug is currently approved in the United States for the treatment of infantile spasms, Questcor said.
Infantile spasm is a seizure disorder of early childhood also known as West Syndrome. Typically, the child suffers a sudden bending forward and stiffening of the body, arms, and legs; there can also be arching of the torso. The spasms may be connected with later conditions such as cerebral palsy, epilepsy, and mental retardation.
Published August 23, 2006 by the Silicon Valley/San Jose Business Journal
Ausführlichere Infos gibt's hier:
http://phx.corporate-ir.net/phoenix.zhtml?c=89528&p=irol-new…
Werde ich womöglich doch noch reich?
Gruß
Antwort auf Beitrag Nr.: 23.361.612 von OpaFritzOtto am 08.08.06 22:46:55Moin,
nach dem Rücksetzer ist die Aktie aus meiner Sicht wieder zum "Kaufen" freigegeben.
In den News spricht Questcor von einem "Milestone". Auf der Pressekonferenz werden wir vielleicht mehr sehen.
Ich habe mir heute noch ein paar Aktien gekauft. Haltefrist bis Dez. 07
Questcor Announces Initiation of Clinical Program for QSC-001
UNION CITY, Calif.--(BUSINESS WIRE)--Nov. 27, 2006--Questcor Pharmaceuticals, Inc. (AMEX:QSC) announced today the initiation of patient dosing under its investigational new drug (IND) application with the U.S. Food & Drug Administration (FDA) for QSC-001, a unique orally disintegrating tablet (ODT) formulation of hydrocodone bitartrate and acetaminophen (HB/APAP) for the treatment of moderate to moderately severe pain. QSC-001 was formulated for Questcor by Eurand and will utilize Eurand's proprietary Microcaps(R) taste-masking and AdvaTab(TM) ODT technologies. Questcor owns the world-wide rights to commercialize QSC-001 and Eurand will exclusively supply the product and receive a royalty on product sales.
HB/APAP, in its variety of strengths, is one of the most frequently prescribed products in the United States with over 100 million prescriptions written in the past year according to Wolters Kluwer. HB/APAP is one of the five most frequently prescribed products by Neurologists, who accounted for over one million prescriptions. There are currently no ODT formulations of HB/APAP available in the United States.
"The successful initiation of our first clinical development program represents an important milestone in Questcor's evolution into a leading CNS-focused specialty pharmaceutical company. We believe that QSC-001 could fill a critical gap in the treatment of pain and represents a tremendous opportunity for Questcor," commented James Fares, Questcor's President and CEO. "Neurologists prescribe pain medication for a large number of their patients, particularly those with Multiple Sclerosis, Headache, Chronic Pain, and Spinal lesions. For the many individuals who experience significant difficulty swallowing pills, we believe QSC-001 represents a valuable option for the treatment of their pain."
Questcor expects to file the QSC-001 New Drug Application with the FDA in the second half of 2007. Eurand will receive milestone payments upon the achievement of certain development milestones.
About Eurand's ODT Technology: AdvaTab(TM) can be combined with Eurand's Microcaps(R) taste-masking technology to provide an ODT with a pleasant taste. In addition, AdvaTab(TM) tablets dissolve rapidly in the mouth within 15 to 30 seconds, and the smooth mixture of carrier excipients and taste-masked drug granules is suitable for delivering high drug doses. Modified-release drug granules can also be incorporated into the AdvaTab(TM) dosage form to provide a fast-dissolve tablet with sustained-release properties. AdvaTab(TM) tablets can be packaged in either bottles or blisters.
About Eurand: Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. The company has had three products approved by the FDA since 2001 and has a pipeline of products in development both for its co-development partners and its proprietary portfolio. The company's lead product candidate, a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and other diseases, is currently undergoing Phase III clinical trials in the United States. Eurand's technology platforms include: bioavailability enhancement of poorly soluble drugs, customized release, taste masking/fast-dissolving formulations, and drug conjugation. Eurand is an established business with manufacturing and research facilities in the United States, Italy and France. For more information, visit Eurand's website at www.eurand.com.
About Questcor - Questcor Pharmaceuticals, Inc.(R) (AMEX:QSC) is a specialty pharmaceutical company that develops and commercializes novel therapeutics for the treatment of neurological disorders. Questcor currently markets H.P. Acthar(R) Gel (repository corticotropin injection), an injectable drug indicated for the treatment of exacerbations associated with multiple sclerosis and Doral(R) (quazepam), that is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.
Note: Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Such statements are subject to certain factors, which may cause Questcor's results to differ from those reported herein. Factors that may cause such differences include, but are not limited to, Questcor's ability to accurately forecast and create the demand for its products, the gross margin achieved from the sale of its products, Questcor's ability to enforce its product returns policy, the accuracy of the prescription data purchased from independent third parties by Questcor, the sell-through by Questcor's distributors, the inventories carried by Questcor's distributors, and the expenses and other cash needs for the upcoming periods, Questcor's ability to obtain finished goods from its sole source contract manufacturers on a timely basis if at all, Questcor's potential future need for additional funding, Questcor's ability to utilize its net operating loss carry forwards to reduce income taxes on the sale of its non-core products, research and development risks, uncertainties regarding Questcor's intellectual property and the uncertainty of receiving required regulatory approvals in a timely way, or at all, and the ability of Questcor to implement its strategy and acquire products and, if acquired, to market them successfully, as well as the risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2005 and other documents filed with the Securities and Exchange Commission. The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.
Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
CONTACT: Questcor Pharmaceuticals, Inc.
Eric Liebler, 510-400-0700
IR@Questcor.com
SOURCE: Questcor Pharmaceuticals, Inc.
Hier die angekündigte Pressekonferenz:
Questcor to Present at BMO Capital Markets Focus on Healthcare 2006 Investor Conference
UNION CITY, Calif.--(BUSINESS WIRE)--Dec. 4, 2006--James L. Fares, President and CEO of Questcor Pharmaceuticals, Inc. (AMEX:QSC), will give a company update at the BMO Capital Markets Focus on Healthcare 2006 Investor Conference. The conference will be held at the Millennium Broadway Hotel, 145 West 44th Street in New York City. Mr. Fares will make his presentation on Thursday, December 7 at 8:45 am EST.
The presentation will be webcast and is accessible at the following link, http://www.bmocm.com/conferences/healthcare2006 or by visiting Questcor's website, where the presentation will be archived for up to two weeks following the event, at www.questcor.com.
About Questcor -- Questcor Pharmaceuticals, Inc.(R) (AMEX:QSC) is a specialty pharmaceutical company that develops and commercializes novel therapeutics for the treatment of neurological disorders. Questcor currently markets H.P. Acthar(R) Gel (repository corticotropin injection), an injectable drug indicated for the treatment of exacerbations associated with multiple sclerosis and Doral(R) (quazepam), that is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.
CONTACT: Questcor Pharmaceuticals, Inc.
Eric Liebler, 510-400-0740
IR@Questcor.com
SOURCE: Questcor Pharmaceuticals, Inc.
Die Aktie lebt!
nach dem Rücksetzer ist die Aktie aus meiner Sicht wieder zum "Kaufen" freigegeben.
In den News spricht Questcor von einem "Milestone". Auf der Pressekonferenz werden wir vielleicht mehr sehen.
Ich habe mir heute noch ein paar Aktien gekauft. Haltefrist bis Dez. 07
Questcor Announces Initiation of Clinical Program for QSC-001
UNION CITY, Calif.--(BUSINESS WIRE)--Nov. 27, 2006--Questcor Pharmaceuticals, Inc. (AMEX:QSC) announced today the initiation of patient dosing under its investigational new drug (IND) application with the U.S. Food & Drug Administration (FDA) for QSC-001, a unique orally disintegrating tablet (ODT) formulation of hydrocodone bitartrate and acetaminophen (HB/APAP) for the treatment of moderate to moderately severe pain. QSC-001 was formulated for Questcor by Eurand and will utilize Eurand's proprietary Microcaps(R) taste-masking and AdvaTab(TM) ODT technologies. Questcor owns the world-wide rights to commercialize QSC-001 and Eurand will exclusively supply the product and receive a royalty on product sales.
HB/APAP, in its variety of strengths, is one of the most frequently prescribed products in the United States with over 100 million prescriptions written in the past year according to Wolters Kluwer. HB/APAP is one of the five most frequently prescribed products by Neurologists, who accounted for over one million prescriptions. There are currently no ODT formulations of HB/APAP available in the United States.
"The successful initiation of our first clinical development program represents an important milestone in Questcor's evolution into a leading CNS-focused specialty pharmaceutical company. We believe that QSC-001 could fill a critical gap in the treatment of pain and represents a tremendous opportunity for Questcor," commented James Fares, Questcor's President and CEO. "Neurologists prescribe pain medication for a large number of their patients, particularly those with Multiple Sclerosis, Headache, Chronic Pain, and Spinal lesions. For the many individuals who experience significant difficulty swallowing pills, we believe QSC-001 represents a valuable option for the treatment of their pain."
Questcor expects to file the QSC-001 New Drug Application with the FDA in the second half of 2007. Eurand will receive milestone payments upon the achievement of certain development milestones.
About Eurand's ODT Technology: AdvaTab(TM) can be combined with Eurand's Microcaps(R) taste-masking technology to provide an ODT with a pleasant taste. In addition, AdvaTab(TM) tablets dissolve rapidly in the mouth within 15 to 30 seconds, and the smooth mixture of carrier excipients and taste-masked drug granules is suitable for delivering high drug doses. Modified-release drug granules can also be incorporated into the AdvaTab(TM) dosage form to provide a fast-dissolve tablet with sustained-release properties. AdvaTab(TM) tablets can be packaged in either bottles or blisters.
About Eurand: Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. The company has had three products approved by the FDA since 2001 and has a pipeline of products in development both for its co-development partners and its proprietary portfolio. The company's lead product candidate, a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and other diseases, is currently undergoing Phase III clinical trials in the United States. Eurand's technology platforms include: bioavailability enhancement of poorly soluble drugs, customized release, taste masking/fast-dissolving formulations, and drug conjugation. Eurand is an established business with manufacturing and research facilities in the United States, Italy and France. For more information, visit Eurand's website at www.eurand.com.
About Questcor - Questcor Pharmaceuticals, Inc.(R) (AMEX:QSC) is a specialty pharmaceutical company that develops and commercializes novel therapeutics for the treatment of neurological disorders. Questcor currently markets H.P. Acthar(R) Gel (repository corticotropin injection), an injectable drug indicated for the treatment of exacerbations associated with multiple sclerosis and Doral(R) (quazepam), that is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.
Note: Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Such statements are subject to certain factors, which may cause Questcor's results to differ from those reported herein. Factors that may cause such differences include, but are not limited to, Questcor's ability to accurately forecast and create the demand for its products, the gross margin achieved from the sale of its products, Questcor's ability to enforce its product returns policy, the accuracy of the prescription data purchased from independent third parties by Questcor, the sell-through by Questcor's distributors, the inventories carried by Questcor's distributors, and the expenses and other cash needs for the upcoming periods, Questcor's ability to obtain finished goods from its sole source contract manufacturers on a timely basis if at all, Questcor's potential future need for additional funding, Questcor's ability to utilize its net operating loss carry forwards to reduce income taxes on the sale of its non-core products, research and development risks, uncertainties regarding Questcor's intellectual property and the uncertainty of receiving required regulatory approvals in a timely way, or at all, and the ability of Questcor to implement its strategy and acquire products and, if acquired, to market them successfully, as well as the risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2005 and other documents filed with the Securities and Exchange Commission. The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.
Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
CONTACT: Questcor Pharmaceuticals, Inc.
Eric Liebler, 510-400-0700
IR@Questcor.com
SOURCE: Questcor Pharmaceuticals, Inc.
Hier die angekündigte Pressekonferenz:
Questcor to Present at BMO Capital Markets Focus on Healthcare 2006 Investor Conference
UNION CITY, Calif.--(BUSINESS WIRE)--Dec. 4, 2006--James L. Fares, President and CEO of Questcor Pharmaceuticals, Inc. (AMEX:QSC), will give a company update at the BMO Capital Markets Focus on Healthcare 2006 Investor Conference. The conference will be held at the Millennium Broadway Hotel, 145 West 44th Street in New York City. Mr. Fares will make his presentation on Thursday, December 7 at 8:45 am EST.
The presentation will be webcast and is accessible at the following link, http://www.bmocm.com/conferences/healthcare2006 or by visiting Questcor's website, where the presentation will be archived for up to two weeks following the event, at www.questcor.com.
About Questcor -- Questcor Pharmaceuticals, Inc.(R) (AMEX:QSC) is a specialty pharmaceutical company that develops and commercializes novel therapeutics for the treatment of neurological disorders. Questcor currently markets H.P. Acthar(R) Gel (repository corticotropin injection), an injectable drug indicated for the treatment of exacerbations associated with multiple sclerosis and Doral(R) (quazepam), that is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.
CONTACT: Questcor Pharmaceuticals, Inc.
Eric Liebler, 510-400-0740
IR@Questcor.com
SOURCE: Questcor Pharmaceuticals, Inc.
Die Aktie lebt!
Antwort auf Beitrag Nr.: 25.972.527 von OpaFritzOtto am 06.12.06 15:41:08Moin,
sieht so aus als wäre ich momentan "Alleinunterhalter". Macht nicht viel Spaß!
Die News haben der Aktie Aufwind gegeben. 2007 sollten wir meiner Meinung nach allerdings noch höhere Kurse sehen.
Moin Moin,
Opafritzotto
sieht so aus als wäre ich momentan "Alleinunterhalter". Macht nicht viel Spaß!
Die News haben der Aktie Aufwind gegeben. 2007 sollten wir meiner Meinung nach allerdings noch höhere Kurse sehen.
Moin Moin,
Opafritzotto
Antwort auf Beitrag Nr.: 26.008.351 von OpaFritzOtto am 07.12.06 21:40:11Keine Panik, ich bin noch da!
Dass das Highlight der Präsentation offensichtlich die Ausgabe von Schnäppchenaktien ist, ist dann schon eher etwas ernüchternd...
Gruß
rohbi
Dass das Highlight der Präsentation offensichtlich die Ausgabe von Schnäppchenaktien ist, ist dann schon eher etwas ernüchternd...
Gruß
rohbi
Habe mal meinen Account wiederbelebt, denn ich war überrascht, dass Questcor hier überhaupt schon mal erwähnt wurde.
Mir ist das Unternehmen eher zufällig vor ca. zwei Wochen aufgefallen und nachdem ich ein wenig recherchierte, habe ich die letzten Tage ein kleine Position zusammengekauft (Kurs in Frankfurt liegt heute übrigens wieder einmal unter US-Schlusskurs *bg*).
Ausgangspunkt für meinen Kauf war übrigens folgende Analyse (nachzulesen unter http://messages.finance.yahoo.com/mb/QSC):" target="_blank" rel="nofollow ugc noopener"> http://messages.finance.yahoo.com/mb/QSC):
The year 2007 is going to be a huge year for Questcor Pharmaceuticals, in terms of company growth, and PPS growth. Below I have provided my thoughts, and will await intelligent conversation by all message board members.
My personal outlook for Questcor in 2007 is as follows...
Currently the PPS has begun to stabilize in the 1.40 to 1.50 price range, and will most likely remain there, until positive news is released.
Sigma-Tau has recently sold 9,402,890 shares to Iverlochy and Chaumiere, whom they own 100% of. This in fact was not a sell, it was a re-shuffling of their position. (The reason's behind such a move are unknown, and in due time will present themselves.)
The Sigma-Tau brothers and Aptifin, currently own 4,752,663 shares of Questcor, and will most likely retain this position, as they have done so for the past 4 years.
Sigma-Tau re-shuffled the 9,402,890 shares at a price of 1.50 per share, so apparently the PPS was an intelligent move at the time of action. (The question is, would they make a move like this in attempt to devalue their own investment, or was it a stratigic move which will become visible in the months or years to come?)
Furthermore, Sigma-Tau continues to truly own in excess of 14 million shares of Questcor, and I see no signs of them stepping away from their investment at this point in time. (Sigma-Tau began investing in Questcor back in the fall of 2001, which was 6 years ago.)
It is of most interest that investors note the recent moves Sigma-Tau has made in terms of Dor Biopharmaceuticals. Also pay close attention to the amount of shares Sigma-Tau owns in RGN, and SCLN. (The Cavazza brothers have built and empire out of Sigma-Tau ...2400 employees..., and have a proven track record of success not only in the pharmaceutical arena, but also the investment arena.)
In February 2005, Jim Fares took the helm of Questcor. The approximate 5 months leading up to this hiring Albert Hansen was the interm CEO. It is safe to say that he played a major role in this decision, and Mr. Hansen should be applauded for his hard work in securing such a qualified individual.
Casamento and Morris went their separate ways in the fall of 2004. Most likely these individuals parted ways with Questcor, when the three biggest investors voted in unison at the Spring 2004 Annual Shareholders Meeting. (Sanders Morris Harris / Broadwood / Sigma-Tau) This was the beginning of the end for these two, over paid, underperforming individuals.
Not only did this signal the end for Casamento and Morris, it signaled the end for many other individuals who for years collected unrealistic salaries and options, for a company of this size. Board of Directors of the old mentality whom had little to offer, slowly began to disappear in 2005, and today the Board of Directors is "locked and loaded"... they want Questcor to be successful, and most importantly with success comes a higher PPS!
Curtain opens, in comes Jim Fares in February 2005, with the PPS at a horrific level of .40 - .50 cents.
When Jim Fares took over Questcor in February 2005, the company was truly not in good shape. The company had a few products but was ultimately underperforming in all aspects. This underperformance was brought about by having too many "irons", in too many "different fires".
Acthar Gel sales were good in terms of the orginal purchase price of the product ($400K - the deal was made by Ken Greathouse.), but the product's inventory controls, expirations, returns, etc., was taking a huge chunk out of the future revenues. The product had huge growth in the beginning due to it not being available to the general public, but eventually it began to flat-line in sales by 2004. (David Medeiros played witness to this situation)
Nascobol was purchased for $18 million, in the summer of 2003. This product may have been very significant over the long term, but it's cost was steep for Questcor at the time. The $10 million PP in January of 2003, was used for Nascobol's purchase in that summer, and we will never know how large this product would have been. The "Questcor change in focus" announced in April 2005 by Jim Fares, led to it's being sold off.
Ethamolin and Glofil also were sold off. The inventory controls, returns, etc. for Ethamolin were horrendous, and Glofil was almostly entirely useless in terms of revenues for Questcor.
As anyone can see, these products were all over the board. Therefore previous management was never able to focus their vision. "Too many irons', and "Too many fires".
In October 2005, Nascobol, Ethamolin, and Glofil were sold for $28.3 million dollars, making Questcor a one product company.
At this point we can now analyze Jim Fares, and his decisions which have shaped Questcor from February 2005 to Jaunary 2007. (Approximately 2 years.)
1.) The first action taken by Jim Fares as CEO was to focus Questcor in one area, therefore making it "special". (April 2005, Questcor changes its focus to being a specialty CNS focused pharmaceutical company. One "fire" to put a lot of "irons" into.)
2.) The second action taken by Jim Fares as CEO was to mend a faultering relationship with Sigma-Tau. Greg LaPonte was quickly added to the Questcor Board of Directors, therefore allowing Sigma-Tau a say in the future direction of the company. (The VSL #3 deal was finished, Casamento and Morris were now gone, and a fresh start to the relationship could begin.)
3.) The third action taken by Jim Fares was to begin to add qualified individuals to Questcor. Jim Fares found these individuals by way of previous CNS experience, and many of these individuals had a positive working relationship in the past.
4.) Fourth... Jim Fares shops around in search of a buyer for Nascobol, Ethamolin, and Glofil. He proceeds to package all three products together for a sale of $28.3 million dollars in October 2005. Questcor can now pay off the Series B preferred stock, and have working capital for all aspects of the company.
5.) Jim Fares and fellow management begin to purchase quite a few shares of Questcor on the open market in the fourth quarter 2005. This shows the investing public that "they have faith in their vision, and are willing to put their own personal money where their mouth's are". [Nachtrag: in 2006 gingen die Insiderkäufe bei Kursen zwischen 1,50 - 1,80 US$ weiter (aktuell 1,45 US$)]
6.) Jim Fares proceeds to hire 40 new sales reps with significant pharmaceutical experience in January-February 2006. These individuals will now be completely focused on growing the sales of Acthar Gel and will be fully trained by the end of the 1st quarter 2006...
7.) 4th Quarter 2005 numbers are released at the beginning of March 2006. The numbers are horrible based on the fact that Questcor revenues come in at $1.8 million. Acthar Gel was the main driver of revenues for the quarter with $1.5 million in sales. The other 3 products were sold in October 2005, so revenues dropped significantly.
(This in fact is the turning point.)
4th Quarter 2005, released March 9th, 2006.
4th Quarter 2005 earnings were .10 cents a share, and this number was based on the product revenues, and the sale of Nascobol, Ethamolin, and Glofil.
Sales of Acthar Gel totaled approximately $1.5 million.
_____________________________________________________ _______
* 4th Quarter, 2005 * Revenue was $1.8 Million *
* 1st Quarter, 2006 * Revenue was $2.0 Million *
* 2nd Quarter, 2006 * Revenue was $3.3 Million *
* 3rd Quarter, 2006 * Revenue was $4.0 Million *
_____________________________________________________ _______
We can see the trend which is forming Quarter over Quarter, so here are my caluculations for the 4th Quarter 2006, which will most likely be released in the beginning of March 2007...
My calculations show Acthar Gel sales totaling $4.4 - $4.5 million for the 4th quarter, which would represent an increase of approximately 15-20% over the 3rd quarter.
My calculations show Acthar Gel sales totaling $4.4 -$4.5 million for the 4th quarter, which would represent an increase of approximately 250 - 300% over 4th quarter 2005.
My calculations show Acthar Gel Sales totaling $13.5 million for 2006, which would represent an increase of approximately 50 - 55% over $8.5 million for 2005.
My calculations show Doral Sales totaling approximately $400,000 thousand, which would represent an increase of approximately 70% over the 3rd quarter 2006.
* I am estimating overall sales for the 4th Quarter of 2006 to be equivalent to $4.8 million with a loss of approximately .01 - .02 per share. *
* With the recent "shelf" which was done in December 2006 equating to approximately .188 cents a share.... 4th Quarter 2006 earnings should be approximately .17 cents.
A profit of .17 cents a share for the 4th quarter of 2006, would represent an increase of 70% in share value compared to the 4th quarter 2005. (.10 cents 4th quarter 2005)
A profit of .17 cents a share for the 4th quarter of 2006, would represent and increase of an "unbelievable percentage" as compared to losing, .03 cents a share in the 3rd quarter of 2006.
The losses for the 1st, 2nd, and 3rd Quarters added to the gain of .17 cents in the 4th quarter of 2006, would show Questcor at EPS of approximately 0.0 for the year.
Questcor as of December 31st 2006, should have approximately $21 million in cash, to work on QSC-001, make mile stone payments for Doral, further Acthar studies, aquire another product or two, fund operations, etc....
You now have a company which is break-even, has a solid cash position, have approved/growing products, have a research pipeline, and solid management!
Fares has just created, YES you guessed it.... "A specialty CNS pharmaceutical company, which is now poised for huge growth over the next couple of years!
Moving forward we ask ourselves, "so how and when, does the PPS begin to increase"? Well, this answer doesn't have an answer, but I do believe that $1.40 - $1.50 is a great area to be buying at!
The lows we saw in October 2006, will have most likely have been the bottom. If I'm guessing correctly it was $1.05 - $1.10.
In the 3rd Quarter 2006, Questcor increased their employee base by 10%. This increase should be refected by way of sales in the first quarter of 2007.
In November 2006, Questcor announced the initiation of a clinical program called QSC-001, and is planning on filing an NDA with the FDA in the 2nd Half of 2007. Most likely we will be informed of the progress by way of PR's throughout the spring/summer of 2007.
In December 2006, Questcor showcased 6 new papers that were published on HP Acthar Gel at the American Epilepsy Society Conference.(I look forward to Questcor presenting at more conferences in the near future, and this will most likely draw more investor interest.)
In December 2006, Questcor raised approximately $13 million dollars by way of issuing shares to insiders at $1.45, and other interested investors at $1.20. (Personally I didn't like the fact of selling shares at $1.20, but this does leave Questcor with a very solid cash position going forward.)
Currently 3 Phase IV trials are being conducted with respects to HP Acthar Gel, and results of these trials are expected first quarter of 2007. (Three significant PR's to look forward to, which should have a significant impact on the stock price.)
Fourth Quarter Earnings will most likely be announced in the beginning of March 2007, and should have a very significant impact on the stock price.
The FDA is set to respond to Questcor's sNDA for IS, in regards to Acthar Gel on April 23rd, 2007. If approval is granted, Questcor has significant leverage in pricing the product accordingly. (Remember Acthar Gel is now covered by Medicare and Medicade, which wasn't the case a couple of years ago.)
The effect of the FDA's decision will have a very significant impact on revenue growth throughout the second half of 2007, so it is of utmost importance to complete the Phase IV studies as soon as possible.
In closing I believe Questcor is headed in the right direction, and that 2007 will be one of the most exciting years in this companies history. I personally am excited to be an investor of this company at this time, and look forward to a huge 2007!
Never forget to do your own research.
Mir ist das Unternehmen eher zufällig vor ca. zwei Wochen aufgefallen und nachdem ich ein wenig recherchierte, habe ich die letzten Tage ein kleine Position zusammengekauft (Kurs in Frankfurt liegt heute übrigens wieder einmal unter US-Schlusskurs *bg*).
Ausgangspunkt für meinen Kauf war übrigens folgende Analyse (nachzulesen unter http://messages.finance.yahoo.com/mb/QSC):" target="_blank" rel="nofollow ugc noopener"> http://messages.finance.yahoo.com/mb/QSC):
The year 2007 is going to be a huge year for Questcor Pharmaceuticals, in terms of company growth, and PPS growth. Below I have provided my thoughts, and will await intelligent conversation by all message board members.
My personal outlook for Questcor in 2007 is as follows...
Currently the PPS has begun to stabilize in the 1.40 to 1.50 price range, and will most likely remain there, until positive news is released.
Sigma-Tau has recently sold 9,402,890 shares to Iverlochy and Chaumiere, whom they own 100% of. This in fact was not a sell, it was a re-shuffling of their position. (The reason's behind such a move are unknown, and in due time will present themselves.)
The Sigma-Tau brothers and Aptifin, currently own 4,752,663 shares of Questcor, and will most likely retain this position, as they have done so for the past 4 years.
Sigma-Tau re-shuffled the 9,402,890 shares at a price of 1.50 per share, so apparently the PPS was an intelligent move at the time of action. (The question is, would they make a move like this in attempt to devalue their own investment, or was it a stratigic move which will become visible in the months or years to come?)
Furthermore, Sigma-Tau continues to truly own in excess of 14 million shares of Questcor, and I see no signs of them stepping away from their investment at this point in time. (Sigma-Tau began investing in Questcor back in the fall of 2001, which was 6 years ago.)
It is of most interest that investors note the recent moves Sigma-Tau has made in terms of Dor Biopharmaceuticals. Also pay close attention to the amount of shares Sigma-Tau owns in RGN, and SCLN. (The Cavazza brothers have built and empire out of Sigma-Tau ...2400 employees..., and have a proven track record of success not only in the pharmaceutical arena, but also the investment arena.)
In February 2005, Jim Fares took the helm of Questcor. The approximate 5 months leading up to this hiring Albert Hansen was the interm CEO. It is safe to say that he played a major role in this decision, and Mr. Hansen should be applauded for his hard work in securing such a qualified individual.
Casamento and Morris went their separate ways in the fall of 2004. Most likely these individuals parted ways with Questcor, when the three biggest investors voted in unison at the Spring 2004 Annual Shareholders Meeting. (Sanders Morris Harris / Broadwood / Sigma-Tau) This was the beginning of the end for these two, over paid, underperforming individuals.
Not only did this signal the end for Casamento and Morris, it signaled the end for many other individuals who for years collected unrealistic salaries and options, for a company of this size. Board of Directors of the old mentality whom had little to offer, slowly began to disappear in 2005, and today the Board of Directors is "locked and loaded"... they want Questcor to be successful, and most importantly with success comes a higher PPS!
Curtain opens, in comes Jim Fares in February 2005, with the PPS at a horrific level of .40 - .50 cents.
When Jim Fares took over Questcor in February 2005, the company was truly not in good shape. The company had a few products but was ultimately underperforming in all aspects. This underperformance was brought about by having too many "irons", in too many "different fires".
Acthar Gel sales were good in terms of the orginal purchase price of the product ($400K - the deal was made by Ken Greathouse.), but the product's inventory controls, expirations, returns, etc., was taking a huge chunk out of the future revenues. The product had huge growth in the beginning due to it not being available to the general public, but eventually it began to flat-line in sales by 2004. (David Medeiros played witness to this situation)
Nascobol was purchased for $18 million, in the summer of 2003. This product may have been very significant over the long term, but it's cost was steep for Questcor at the time. The $10 million PP in January of 2003, was used for Nascobol's purchase in that summer, and we will never know how large this product would have been. The "Questcor change in focus" announced in April 2005 by Jim Fares, led to it's being sold off.
Ethamolin and Glofil also were sold off. The inventory controls, returns, etc. for Ethamolin were horrendous, and Glofil was almostly entirely useless in terms of revenues for Questcor.
As anyone can see, these products were all over the board. Therefore previous management was never able to focus their vision. "Too many irons', and "Too many fires".
In October 2005, Nascobol, Ethamolin, and Glofil were sold for $28.3 million dollars, making Questcor a one product company.
At this point we can now analyze Jim Fares, and his decisions which have shaped Questcor from February 2005 to Jaunary 2007. (Approximately 2 years.)
1.) The first action taken by Jim Fares as CEO was to focus Questcor in one area, therefore making it "special". (April 2005, Questcor changes its focus to being a specialty CNS focused pharmaceutical company. One "fire" to put a lot of "irons" into.)
2.) The second action taken by Jim Fares as CEO was to mend a faultering relationship with Sigma-Tau. Greg LaPonte was quickly added to the Questcor Board of Directors, therefore allowing Sigma-Tau a say in the future direction of the company. (The VSL #3 deal was finished, Casamento and Morris were now gone, and a fresh start to the relationship could begin.)
3.) The third action taken by Jim Fares was to begin to add qualified individuals to Questcor. Jim Fares found these individuals by way of previous CNS experience, and many of these individuals had a positive working relationship in the past.
4.) Fourth... Jim Fares shops around in search of a buyer for Nascobol, Ethamolin, and Glofil. He proceeds to package all three products together for a sale of $28.3 million dollars in October 2005. Questcor can now pay off the Series B preferred stock, and have working capital for all aspects of the company.
5.) Jim Fares and fellow management begin to purchase quite a few shares of Questcor on the open market in the fourth quarter 2005. This shows the investing public that "they have faith in their vision, and are willing to put their own personal money where their mouth's are". [Nachtrag: in 2006 gingen die Insiderkäufe bei Kursen zwischen 1,50 - 1,80 US$ weiter (aktuell 1,45 US$)]
6.) Jim Fares proceeds to hire 40 new sales reps with significant pharmaceutical experience in January-February 2006. These individuals will now be completely focused on growing the sales of Acthar Gel and will be fully trained by the end of the 1st quarter 2006...
7.) 4th Quarter 2005 numbers are released at the beginning of March 2006. The numbers are horrible based on the fact that Questcor revenues come in at $1.8 million. Acthar Gel was the main driver of revenues for the quarter with $1.5 million in sales. The other 3 products were sold in October 2005, so revenues dropped significantly.
(This in fact is the turning point.)
4th Quarter 2005, released March 9th, 2006.
4th Quarter 2005 earnings were .10 cents a share, and this number was based on the product revenues, and the sale of Nascobol, Ethamolin, and Glofil.
Sales of Acthar Gel totaled approximately $1.5 million.
_____________________________________________________ _______
* 4th Quarter, 2005 * Revenue was $1.8 Million *
* 1st Quarter, 2006 * Revenue was $2.0 Million *
* 2nd Quarter, 2006 * Revenue was $3.3 Million *
* 3rd Quarter, 2006 * Revenue was $4.0 Million *
_____________________________________________________ _______
We can see the trend which is forming Quarter over Quarter, so here are my caluculations for the 4th Quarter 2006, which will most likely be released in the beginning of March 2007...
My calculations show Acthar Gel sales totaling $4.4 - $4.5 million for the 4th quarter, which would represent an increase of approximately 15-20% over the 3rd quarter.
My calculations show Acthar Gel sales totaling $4.4 -$4.5 million for the 4th quarter, which would represent an increase of approximately 250 - 300% over 4th quarter 2005.
My calculations show Acthar Gel Sales totaling $13.5 million for 2006, which would represent an increase of approximately 50 - 55% over $8.5 million for 2005.
My calculations show Doral Sales totaling approximately $400,000 thousand, which would represent an increase of approximately 70% over the 3rd quarter 2006.
* I am estimating overall sales for the 4th Quarter of 2006 to be equivalent to $4.8 million with a loss of approximately .01 - .02 per share. *
* With the recent "shelf" which was done in December 2006 equating to approximately .188 cents a share.... 4th Quarter 2006 earnings should be approximately .17 cents.
A profit of .17 cents a share for the 4th quarter of 2006, would represent an increase of 70% in share value compared to the 4th quarter 2005. (.10 cents 4th quarter 2005)
A profit of .17 cents a share for the 4th quarter of 2006, would represent and increase of an "unbelievable percentage" as compared to losing, .03 cents a share in the 3rd quarter of 2006.
The losses for the 1st, 2nd, and 3rd Quarters added to the gain of .17 cents in the 4th quarter of 2006, would show Questcor at EPS of approximately 0.0 for the year.
Questcor as of December 31st 2006, should have approximately $21 million in cash, to work on QSC-001, make mile stone payments for Doral, further Acthar studies, aquire another product or two, fund operations, etc....
You now have a company which is break-even, has a solid cash position, have approved/growing products, have a research pipeline, and solid management!
Fares has just created, YES you guessed it.... "A specialty CNS pharmaceutical company, which is now poised for huge growth over the next couple of years!
Moving forward we ask ourselves, "so how and when, does the PPS begin to increase"? Well, this answer doesn't have an answer, but I do believe that $1.40 - $1.50 is a great area to be buying at!
The lows we saw in October 2006, will have most likely have been the bottom. If I'm guessing correctly it was $1.05 - $1.10.
In the 3rd Quarter 2006, Questcor increased their employee base by 10%. This increase should be refected by way of sales in the first quarter of 2007.
In November 2006, Questcor announced the initiation of a clinical program called QSC-001, and is planning on filing an NDA with the FDA in the 2nd Half of 2007. Most likely we will be informed of the progress by way of PR's throughout the spring/summer of 2007.
In December 2006, Questcor showcased 6 new papers that were published on HP Acthar Gel at the American Epilepsy Society Conference.(I look forward to Questcor presenting at more conferences in the near future, and this will most likely draw more investor interest.)
In December 2006, Questcor raised approximately $13 million dollars by way of issuing shares to insiders at $1.45, and other interested investors at $1.20. (Personally I didn't like the fact of selling shares at $1.20, but this does leave Questcor with a very solid cash position going forward.)
Currently 3 Phase IV trials are being conducted with respects to HP Acthar Gel, and results of these trials are expected first quarter of 2007. (Three significant PR's to look forward to, which should have a significant impact on the stock price.)
Fourth Quarter Earnings will most likely be announced in the beginning of March 2007, and should have a very significant impact on the stock price.
The FDA is set to respond to Questcor's sNDA for IS, in regards to Acthar Gel on April 23rd, 2007. If approval is granted, Questcor has significant leverage in pricing the product accordingly. (Remember Acthar Gel is now covered by Medicare and Medicade, which wasn't the case a couple of years ago.)
The effect of the FDA's decision will have a very significant impact on revenue growth throughout the second half of 2007, so it is of utmost importance to complete the Phase IV studies as soon as possible.
In closing I believe Questcor is headed in the right direction, and that 2007 will be one of the most exciting years in this companies history. I personally am excited to be an investor of this company at this time, and look forward to a huge 2007!
Never forget to do your own research.
PS: Noch zwei Artikel zu dem sNDA für Acthar in Bezug auf Infantile Spasm über den die FDA bis zum 23. April 2007 entschieden haben muss:
http://www.emedicine.com/neuro/topic171.htm: eie detaillierte Beschreibung der Krankheit (Symptome, Todesraten, Behandlungsmöglichkeiten etc.) inkl. Anzahl der betroffenen Personen)
http://www.finanznachrichten.de/nachrichten-2006-08/artikel-…
23.08.2006 18:56
Questcor beantragt sNDA für Acthar(R) Gel zur Behandlung von West-Syndrom (Infantile Spasms); FDA will Antrag prüfen
Questcor Pharmaceuticals, Inc. (AMEX:QSC) teilte heute mit, dass die US-amerikanische Zulassungsbehörde für Arzneimittel (FDA) der Prüfung des vom Unternehmen gestellten Antrags auf eine beschleunigte Zulassung seiner Supplemental New Drug Application (sNDA) für H.P. Acthar(R) Gel (Depotcorticotropin-Injektion) zur Behandlung des so genannten West-Syndroms (syn. „Infantile Spasms") zustimmte. Questcor geht davon aus, dass die FDA den sNDA-Antrag im zweiten Quartal 2007 bearbeiten wird. In den USA ist derzeit keine zugelassene Behandlungsmethode für das West-Syndrom (Infantile Spasms) verfügbar.
„Die heutige Ankündigung zeigt unser fortgesetztes Engagement für die Behandlung von Krankheiten und Störungen des zentralen Nervensystems", so James Fares, Präsident und CEO von Questcor. „Acthar Gel ist heute ein wichtiges Medikament für die Behandlung des West-Syndroms. Wir sind aber der Überzeugung, dass dieser Antrag die Bedeutung von Acthar Gel bei der Behandlung dieser lebensbedrohlichen Form von Epilepsie im Kindesalter noch unterstreicht. Wir freuen uns auf eine enge Zusammenarbeit mit der FDA während dieses Prüfungsverfahrens."
Die sNDA liefert klinische Daten, die die Erweiterung der Indikation auf der Produktkennzeichnung von Acthar Gel auf das West-Syndrom unterstützen.
Die Informationen enthalten historische Daten zur Verwendung von Acthar Gel bei der Behandlung von West-Syndrom sowie die Ergebnisse aus randomisierten klinischen Studien, in die mehr als 250 Patienten einbezogen waren und die in von Fachleuten geprüfter medizinischer Literatur veröffentlicht wurden.
Über das Web-Syndrom - Das Websyndrom (syn. „Infantile Spasms" oder IS) ist Epilepsie im Kindesalter, die meist im ersten Lebensjahr, üblicherweise zwischen dem 3. und 6. Monat, erstmalig auftritt. Typische Muster für IS sind plötzliches Nachvornebeugen und Versteifen des Körpers, der Arme und Beine; es kann auch eine Krümmung des Rumpfes auftreten. Die Krämpfe stellen sich häufig nach dem Aufwachen ein und dauern üblicherweise 1 bis 5 Sekunden. Die Anfälle treten in Serien auf, dabei kann es vorkommen, dass bei einer Serie 2 bis 100 Krampfanfälle auftreten. Die Kinder können Dutzende von Serien und Hunderte von Krampfanfällen täglich haben. Infantile Spasms hören gewöhnlich im Alter von 5 Jahren auf, häufig erscheinen dann jedoch andere Anfallsleiden. Für IS charakteristisch sind Krampfanfälle, Hypsarrhythmie (EEG-Muster mit auffälligen, unregelmäßigen Wellen) und geistige Behinderung. Bei etwa 30-50% der IS-Fälle wurden weitere neurologische Erkrankungen beobachtet, z. B. zerebrale Lähmung oder Kinderlähmung. IS kommt schätzungsweise bei etwa einer von 2.000 bis 4.000 Lebendgeburten vor. Es handelt sich dabei um die häufigste Art epileptischer Enzephalopathie, bei der eine Epilepsie kognitiven Verfall verursacht. In den USA gibt es derzeit kein zugelassenes Medikament zur Behandlung von IS. Patienten, bei denen diese Krankheit diagnostiziert wurde, werden üblicherweise mit verschiedenen Wirkstoffen behandelt, unter Anderem mit Acthar Gel.
Über Acthar Gel - H.P. Acthar Gel(R) ist ein natürliches Adrenocorticotropes Hormon (ACTH), das so entwickelt wurde, dass nach einer intramuskulären oder subkutanen Injektion eine Abgabe über einen längeren Zeitraum hinweg stattfindet. Acthar Gel ist derzeit indiziert zur Behandlung von akuten Verschlimmerungen bei Multipler Sklerose und bei verschiedenen anderen Krankheiten und Störungen.
http://www.emedicine.com/neuro/topic171.htm: eie detaillierte Beschreibung der Krankheit (Symptome, Todesraten, Behandlungsmöglichkeiten etc.) inkl. Anzahl der betroffenen Personen)
http://www.finanznachrichten.de/nachrichten-2006-08/artikel-…
23.08.2006 18:56
Questcor beantragt sNDA für Acthar(R) Gel zur Behandlung von West-Syndrom (Infantile Spasms); FDA will Antrag prüfen
Questcor Pharmaceuticals, Inc. (AMEX:QSC) teilte heute mit, dass die US-amerikanische Zulassungsbehörde für Arzneimittel (FDA) der Prüfung des vom Unternehmen gestellten Antrags auf eine beschleunigte Zulassung seiner Supplemental New Drug Application (sNDA) für H.P. Acthar(R) Gel (Depotcorticotropin-Injektion) zur Behandlung des so genannten West-Syndroms (syn. „Infantile Spasms") zustimmte. Questcor geht davon aus, dass die FDA den sNDA-Antrag im zweiten Quartal 2007 bearbeiten wird. In den USA ist derzeit keine zugelassene Behandlungsmethode für das West-Syndrom (Infantile Spasms) verfügbar.
„Die heutige Ankündigung zeigt unser fortgesetztes Engagement für die Behandlung von Krankheiten und Störungen des zentralen Nervensystems", so James Fares, Präsident und CEO von Questcor. „Acthar Gel ist heute ein wichtiges Medikament für die Behandlung des West-Syndroms. Wir sind aber der Überzeugung, dass dieser Antrag die Bedeutung von Acthar Gel bei der Behandlung dieser lebensbedrohlichen Form von Epilepsie im Kindesalter noch unterstreicht. Wir freuen uns auf eine enge Zusammenarbeit mit der FDA während dieses Prüfungsverfahrens."
Die sNDA liefert klinische Daten, die die Erweiterung der Indikation auf der Produktkennzeichnung von Acthar Gel auf das West-Syndrom unterstützen.
Die Informationen enthalten historische Daten zur Verwendung von Acthar Gel bei der Behandlung von West-Syndrom sowie die Ergebnisse aus randomisierten klinischen Studien, in die mehr als 250 Patienten einbezogen waren und die in von Fachleuten geprüfter medizinischer Literatur veröffentlicht wurden.
Über das Web-Syndrom - Das Websyndrom (syn. „Infantile Spasms" oder IS) ist Epilepsie im Kindesalter, die meist im ersten Lebensjahr, üblicherweise zwischen dem 3. und 6. Monat, erstmalig auftritt. Typische Muster für IS sind plötzliches Nachvornebeugen und Versteifen des Körpers, der Arme und Beine; es kann auch eine Krümmung des Rumpfes auftreten. Die Krämpfe stellen sich häufig nach dem Aufwachen ein und dauern üblicherweise 1 bis 5 Sekunden. Die Anfälle treten in Serien auf, dabei kann es vorkommen, dass bei einer Serie 2 bis 100 Krampfanfälle auftreten. Die Kinder können Dutzende von Serien und Hunderte von Krampfanfällen täglich haben. Infantile Spasms hören gewöhnlich im Alter von 5 Jahren auf, häufig erscheinen dann jedoch andere Anfallsleiden. Für IS charakteristisch sind Krampfanfälle, Hypsarrhythmie (EEG-Muster mit auffälligen, unregelmäßigen Wellen) und geistige Behinderung. Bei etwa 30-50% der IS-Fälle wurden weitere neurologische Erkrankungen beobachtet, z. B. zerebrale Lähmung oder Kinderlähmung. IS kommt schätzungsweise bei etwa einer von 2.000 bis 4.000 Lebendgeburten vor. Es handelt sich dabei um die häufigste Art epileptischer Enzephalopathie, bei der eine Epilepsie kognitiven Verfall verursacht. In den USA gibt es derzeit kein zugelassenes Medikament zur Behandlung von IS. Patienten, bei denen diese Krankheit diagnostiziert wurde, werden üblicherweise mit verschiedenen Wirkstoffen behandelt, unter Anderem mit Acthar Gel.
Über Acthar Gel - H.P. Acthar Gel(R) ist ein natürliches Adrenocorticotropes Hormon (ACTH), das so entwickelt wurde, dass nach einer intramuskulären oder subkutanen Injektion eine Abgabe über einen längeren Zeitraum hinweg stattfindet. Acthar Gel ist derzeit indiziert zur Behandlung von akuten Verschlimmerungen bei Multipler Sklerose und bei verschiedenen anderen Krankheiten und Störungen.
Antwort auf Beitrag Nr.: 27.481.945 von TwoNE1 am 07.02.07 11:10:37Gute Analyse, allerdings ist seit Anfang Dezember und der Ausgabe der Aktien nichts Richtungsweisendes verkündet worden. Muss nach den vielen Richtungswechseln der vergangenen Jahre nicht unbedingt ein schlechtes Zeichen sein.
QSC wird immer mal wieder in unterschiedlichen Threads andiskutiert oder am Leben erhalten. Passend zur Firma war auch hier nicht unbedingt Stringenz erkennbar.
Ich teile jedenfalls deine Einschätzung und lasse deshalb (wie seit Jahren) meinen Bestand vor sich hin dümpeln...
Gruß
QSC wird immer mal wieder in unterschiedlichen Threads andiskutiert oder am Leben erhalten. Passend zur Firma war auch hier nicht unbedingt Stringenz erkennbar.
Ich teile jedenfalls deine Einschätzung und lasse deshalb (wie seit Jahren) meinen Bestand vor sich hin dümpeln...
Gruß
Antwort auf Beitrag Nr.: 27.482.745 von TwoNE1 am 07.02.07 11:53:11Moin,
sehr gute Zusammenfassung von Questcor Parmaceutical.
Auch von mir wird "Questcor" weiterhin gehalten. Der weitere Verlauf in 2007 sollte sehr viel mehr Klarheit in diese Aktie bringen. Meiner Meinung nach spiegeln sich die Chancen dieser Aktie noch nicht in den Kursen wider.
Ich sehe Questcor auf einem guten Weg und erwarte weit höhere Umsätze und entsprechende Kurse.
Bei Kursen unter 1,00 Euro werde ich nochmals meinen Bestand erweitern.
Opafritzotto
sehr gute Zusammenfassung von Questcor Parmaceutical.
Auch von mir wird "Questcor" weiterhin gehalten. Der weitere Verlauf in 2007 sollte sehr viel mehr Klarheit in diese Aktie bringen. Meiner Meinung nach spiegeln sich die Chancen dieser Aktie noch nicht in den Kursen wider.
Ich sehe Questcor auf einem guten Weg und erwarte weit höhere Umsätze und entsprechende Kurse.
Bei Kursen unter 1,00 Euro werde ich nochmals meinen Bestand erweitern.
Opafritzotto
Antwort auf Beitrag Nr.: 27.559.612 von OpaFritzOtto am 09.02.07 22:24:36Am 12.03. gibt es das Jahresendergebnis
http://news.morningstar.com/news/ViewNews.asp?article=/BW/20…
http://news.morningstar.com/news/ViewNews.asp?article=/BW/20…
Antwort auf Beitrag Nr.: 28.155.808 von fr1 am 06.03.07 21:50:17http://news.morningstar.com/news/ViewNews.asp?article=/BW/20…
Antwort auf Beitrag Nr.: 28.261.535 von fr1 am 12.03.07 21:21:01Moin, moin,
leider waren die Ergebnisse für das 4te Quartal und für das Gesamtjahr 2006 durch das 4te Quartal eher enttäuschend............
Aus meiner Sicht bietet sich ein neues Engagement in diese Aktie momentan nicht an. Der Markt in Amerika spricht eine deutliche Sprache.
Ich habe heute eine Mail Richtung Questcor verschickt, um Antworten auf meine Fragen zu bekommen.
1. Welche Gründe gab es für den Ergebnisrückgang 03/06 auf 04/06?
2. Wie erklärt sich Questcor den kleineren Cashbestand?
3. Gibt es einen FDA Termin bzgl. sNDA Acthar (R)?
4. Wann will Questcor positive Quartalsergebnisse erreichen?
Wer hat weitere Infos?
See you,
Opafritzotto
leider waren die Ergebnisse für das 4te Quartal und für das Gesamtjahr 2006 durch das 4te Quartal eher enttäuschend............
Aus meiner Sicht bietet sich ein neues Engagement in diese Aktie momentan nicht an. Der Markt in Amerika spricht eine deutliche Sprache.
Ich habe heute eine Mail Richtung Questcor verschickt, um Antworten auf meine Fragen zu bekommen.
1. Welche Gründe gab es für den Ergebnisrückgang 03/06 auf 04/06?
2. Wie erklärt sich Questcor den kleineren Cashbestand?
3. Gibt es einen FDA Termin bzgl. sNDA Acthar (R)?
4. Wann will Questcor positive Quartalsergebnisse erreichen?
Wer hat weitere Infos?
See you,
Opafritzotto
Die Zahlen hätten schlimmer sein können, der Hoffnungsträger aber "rejected" durch die FDA!
Gestern (entgültiger) Absturz und Heute (nur) Rebound?
Wo sind die Meinungen?
Gruß
Gestern (entgültiger) Absturz und Heute (nur) Rebound?
Wo sind die Meinungen?
Gruß
Habe heute meine komplette Position verkauft.
Kann es nicht begründen, da ich den Wert schon nach der missglückten Zulassung abgeschrieben hatte und die fundamentale Entwicklung nicht detailliert verfolgt habe.
Ich fühl mich mit dem Kursverlauf der letzten Monate einfach nicht mehr wohl und nehme lieber einen kleinen Gewinn mit, als wieder die Hälfte zu verlieren.
Kann es nicht begründen, da ich den Wert schon nach der missglückten Zulassung abgeschrieben hatte und die fundamentale Entwicklung nicht detailliert verfolgt habe.
Ich fühl mich mit dem Kursverlauf der letzten Monate einfach nicht mehr wohl und nehme lieber einen kleinen Gewinn mit, als wieder die Hälfte zu verlieren.
Ja in welchem Film bin ich denn hier???
http://www2.barchart.com/news.asp?sym=QSC
Wer hätte das gedacht:
3.QT 2007 +0,12$/Share gegenüber 3.QT 2006 -0,03$/Share
1.-3.QT 2007 +0,04$/Share gegenüber 1.-3.QT 2006 -0,12$/Share
Und der Kurs geht ab wie 'ne Rakete...
Hat sonst noch jemand durchgehalten?
http://www2.barchart.com/news.asp?sym=QSC
Wer hätte das gedacht:
3.QT 2007 +0,12$/Share gegenüber 3.QT 2006 -0,03$/Share
1.-3.QT 2007 +0,04$/Share gegenüber 1.-3.QT 2006 -0,12$/Share
Und der Kurs geht ab wie 'ne Rakete...
Hat sonst noch jemand durchgehalten?
Hi Rohbi! Schon fast vergessen. Bin seit 11.2005 zu 0,80€ dabei. was lange währt wird i.d.R gut. Weiter so!
Antwort auf Beitrag Nr.: 32.397.956 von Sinne am 12.11.07 19:53:13Hallo Sinne,
Habe eine erste kleine Position 2002 gekauft. Selbst die ist jetzt im Plus. Im Mai 2005 dann nochmals ordentlich nachgelegt...
Man reibt sich die Augen! Muss mir mal 'ne Lesebrille ausleihen. Ich glaube ich erkenne die Zahlen nicht mehr deutlich. Sind das wirklich schon wieder 50% ???
Gruß
rohbi
Habe eine erste kleine Position 2002 gekauft. Selbst die ist jetzt im Plus. Im Mai 2005 dann nochmals ordentlich nachgelegt...
Man reibt sich die Augen! Muss mir mal 'ne Lesebrille ausleihen. Ich glaube ich erkenne die Zahlen nicht mehr deutlich. Sind das wirklich schon wieder 50% ???
Gruß
rohbi
-Nettoumsatz $14,8 Mio u.$22,7Mio für 3 u. ) Monate bis 30.8.07 im
Vergleich zu $4 Mio u. 9,4 Mio für gleichen Zeitraum in 2006.
-Nettogewinn 3. Quartal 07 + $ 8,4 Mio im Vergleich von Nettoverlust
von $1,5 Mio im 3.Quartal 06
Vergleich zu $4 Mio u. 9,4 Mio für gleichen Zeitraum in 2006.
-Nettogewinn 3. Quartal 07 + $ 8,4 Mio im Vergleich von Nettoverlust
von $1,5 Mio im 3.Quartal 06
Oh Mann, ich fasse es nicht. Das wäre ein schöner Gewinn gewesen...
Mensch. Viel zu früh begonnen. Normalerweise fängt er erst ab Januar an, das hier die Post abgeht. Schaut euch den Chart an. Seit fast 10 Jahren immer das selbe Ende/Anfang des jahres zieht er an und dann....
Schade. Hätte gerne mitgemacht.
@TwoNE1 Tut mir echt leid Junge.
Schade. Hätte gerne mitgemacht.
@TwoNE1 Tut mir echt leid Junge.
Antwort auf Beitrag Nr.: 32.429.415 von Kambyses am 14.11.07 20:17:05Vergiss den Chart. Es wird Geld verdient! Damit kann man die Charttechnik vergessen. Die einzige Frage ist:
Wohin geht die Reise?
Was ist eine angemessene Bewertung?
Meinungen? Infos? Einschätzungen?
Wohin geht die Reise?
Was ist eine angemessene Bewertung?
Meinungen? Infos? Einschätzungen?
Antwort auf Beitrag Nr.: 32.461.539 von rohbi am 16.11.07 23:56:47
Ich hab keine Ahnung warum der Kurs so angezogen hat. Direkte Nachrichten hab ich nicht gefunden.
Ich hab keine Ahnung warum der Kurs so angezogen hat. Direkte Nachrichten hab ich nicht gefunden.
Antwort auf Beitrag Nr.: 32.494.630 von Kambyses am 20.11.07 14:30:21???
Les' mal u. a. hier:
http://phx.corporate-ir.net/phoenix.zhtml?c=89528&p=irol-new…
Les' mal u. a. hier:
http://phx.corporate-ir.net/phoenix.zhtml?c=89528&p=irol-new…
Wow! Der Interims-Präsident Don M. Bailey wird Präsident und CEO und schon wuppt QSC weitere 20% nach oben...
http://phx.corporate-ir.net/phoenix.zhtml?c=89528&p=irol-new…
Hätte mir vor etwa 4 Wochen oder besser einem halben Jahr irgendjemand gesagt, dass QSC einmal an einem Tag 1$ macht, hätte ich ihn für verrückt erklärt! Ich werde noch reich...
Oder weiß jemand mehr?
http://phx.corporate-ir.net/phoenix.zhtml?c=89528&p=irol-new…
Hätte mir vor etwa 4 Wochen oder besser einem halben Jahr irgendjemand gesagt, dass QSC einmal an einem Tag 1$ macht, hätte ich ihn für verrückt erklärt! Ich werde noch reich...
Oder weiß jemand mehr?
Naja, ziemlich aggressives Marketing!
http://www2.barchart.com/news.asp?sym=QSC
Wenn's weiter hilft...
http://www2.barchart.com/news.asp?sym=QSC
Wenn's weiter hilft...
Hat Irgendjemand 'ne Idee, warum Questcor in diesem Umfeld gerade um 17% zulegt?
Ich habe keine Infos gefunden...
Ich habe keine Infos gefunden...
Das Jahr geht ja gut los!
Morgen gibt es vor Börseneröffnung ein Update über den Fortschritt der überarbeiteten Strategie für Acthar:
http://www2.barchart.com/news.asp?sym=QSC
Bin ja mal gespannt!
Der Markt hat es vorab positiv aufgenommen.
SK 6,07 USD +5,2%. In der Spitze sogar 6,24 USD
Gruß und ein erfolgreiches Jahr 2008!
rohbi
Morgen gibt es vor Börseneröffnung ein Update über den Fortschritt der überarbeiteten Strategie für Acthar:
http://www2.barchart.com/news.asp?sym=QSC
Bin ja mal gespannt!
Der Markt hat es vorab positiv aufgenommen.
SK 6,07 USD +5,2%. In der Spitze sogar 6,24 USD
Gruß und ein erfolgreiches Jahr 2008!
rohbi
Ganz gut gehalten in diesem Umfeld!
Die Meldung war nicht sensationell, bestätigt aber den Trend. Mir gefällt vor allem, das der Ausblick vorsichtig ist. Kein trommeln...
Ist noch jemand dabei?
Die Meldung war nicht sensationell, bestätigt aber den Trend. Mir gefällt vor allem, das der Ausblick vorsichtig ist. Kein trommeln...
Ist noch jemand dabei?
In USA wird zunehmend über eine Übernahme, z.B. von Shire, spekuliert.
http://seekingalpha.com/article/65682-is-shire-eying-questco…
Fairer Übernahmepreis wären 12,5 US$ !!!
Warten wir erst mal die Zahlen am 3.4. ab...
http://seekingalpha.com/article/65682-is-shire-eying-questco…
Fairer Übernahmepreis wären 12,5 US$ !!!
Warten wir erst mal die Zahlen am 3.4. ab...
die aktie hält sich überragend in dieser baisse!
nach einer kursverzehnfachung innerhalb eines halben jahres könnte man eigentlich von einer starken korrektur ausgehen, nicht aber so qsc, welche lediglich seitwärts gelaufen ist. das allein ist schon sehr gut, wenn man sich aber mal den gesamtmarkt in dieser phase seit november anschaut, kann man richtig euphorisch werden.
aktien mit genau diesen kursverlaufen muß man suchen, wenn man in baissezeiten die neuen topperformer eines neuen bullenmarktes erkennen will!
wenn die baisse jetzt vorbei sein sollte, ist questcor für mich ein heißer kandidat zum absoluten anführer dieses neuen bullenmarktes!
die fundamentaldaten unterstreichen den kursverlauf.
letztes quartal mit höchstem quartalsgewinn aller zeiten
quartalsumsatzwachstum: 800%
also nicht einfach nur heiße luft mit lehren versprechungen wie bei manchen minenaktien.
ich traue der aktie noch einiges zu. vorausgesetzt natürlich der gesamtmarkt beendet die baisse.
nach einer kursverzehnfachung innerhalb eines halben jahres könnte man eigentlich von einer starken korrektur ausgehen, nicht aber so qsc, welche lediglich seitwärts gelaufen ist. das allein ist schon sehr gut, wenn man sich aber mal den gesamtmarkt in dieser phase seit november anschaut, kann man richtig euphorisch werden.
aktien mit genau diesen kursverlaufen muß man suchen, wenn man in baissezeiten die neuen topperformer eines neuen bullenmarktes erkennen will!
wenn die baisse jetzt vorbei sein sollte, ist questcor für mich ein heißer kandidat zum absoluten anführer dieses neuen bullenmarktes!
die fundamentaldaten unterstreichen den kursverlauf.
letztes quartal mit höchstem quartalsgewinn aller zeiten
quartalsumsatzwachstum: 800%
also nicht einfach nur heiße luft mit lehren versprechungen wie bei manchen minenaktien.
ich traue der aktie noch einiges zu. vorausgesetzt natürlich der gesamtmarkt beendet die baisse.
neues kürzel
statt qsc ab sofort qcor
statt qsc ab sofort qcor
Was ist mit dem Wert los?
Geht ziemlich gut ab in letzter Zeit.
Geht ziemlich gut ab in letzter Zeit.
Hoppla, Gary Sawka ersetzt George Stuart als CFO, prompt gibt es am selben Tag (11.9.) durch Stanford Research und Soleil zwei Kaufempfehlungen und schon geht die Party weiter...
Nicht nur dem schwachen Markt getrotzt, auch noch sehr gute Zahlen:
http://phx.corporate-ir.net/phoenix.zhtml?c=89528&p=irol-new…
Wer auch immer noch dabei ist, ich denke das war's noch nicht. Da sehen wir bald zweistellige Kurse...
http://phx.corporate-ir.net/phoenix.zhtml?c=89528&p=irol-new…
Wer auch immer noch dabei ist, ich denke das war's noch nicht. Da sehen wir bald zweistellige Kurse...
Antwort auf Beitrag Nr.: 35.797.955 von rohbi am 02.11.08 11:58:05ich glaube auch nicht, dass es das schon war mit qcor. wer in diesem markt von ath zu ath läuft zeigt doch klare relative stärke. wenn der gesamtmarkt besser gelaufen wäre, würde qcor wohl mindestens doppelt so hoch stehen.
trotzdem bleibt es schwierig einen richtigen einstiegskurs bei questcor zu finden. die plötzlichen und unberechenbaren kursausschläge nach unten machen jede trendfolgestrategie, die mit stopkursen arbeitet unmöglich. obwohl die aktie sich dieses jahr sehr gut entwickelt hat, bin ich selbst einmal mit -6,6% und einmal mit -11% ausgestoppt worden. somit war qcor dieses jahr mein größter geldvernichter.
trotzdem bleibt es schwierig einen richtigen einstiegskurs bei questcor zu finden. die plötzlichen und unberechenbaren kursausschläge nach unten machen jede trendfolgestrategie, die mit stopkursen arbeitet unmöglich. obwohl die aktie sich dieses jahr sehr gut entwickelt hat, bin ich selbst einmal mit -6,6% und einmal mit -11% ausgestoppt worden. somit war qcor dieses jahr mein größter geldvernichter.
Antwort auf Beitrag Nr.: 35.799.402 von steven_trader am 02.11.08 14:55:21Das ist Pech! Ich stand selbst mehrmals kurz davor, bei diesen Ausschlägen glatt zu stellen. Ich prüfe allerdings bei diesem Wert den Stopp anhand Marktumfeld und Unternehmensmeldungen.
Habe vor 3 1/2-Jahren eine kleine Testposition zu 0,60$ ins Depot genommen und dann ohne Stopp liegen lassen. Hatte zwar langfristig eine positive Entwicklung erwartet aber nicht in dieser Form! Jetzt ziehe ich einen weiten Stopp von etwa 25% unregelmäßig zur Absicherung nach.
In diesem Marktumfeld würde ich aber selbst bei weitem Stopp auch schnell die Reißleine ziehen. Mir erging's bei Valence (Lithiumakkus) ähnlich wie Dir.
Insgesamt sehe ich bei QCOR noch 'ne Menge Potential. Es gibt ein mehr oder weniger konkurenzloses Produkt ACTHAR, das neben fröhlich sprudelnder Gewinne noch weitere Vermarktungsmöglichkeiten (IS) bietet (Studie ab 1.QT 2009 auch für NS und dafür gibt es noch gar kein zugelassenes Medikament!) und das weitere sich bereits im Markt befindendem Produkt DORAL, sowie weitere Produkte in der Pipeline. Und das bei einer MK von nur rund 500 Mio $...
Gruss
Habe vor 3 1/2-Jahren eine kleine Testposition zu 0,60$ ins Depot genommen und dann ohne Stopp liegen lassen. Hatte zwar langfristig eine positive Entwicklung erwartet aber nicht in dieser Form! Jetzt ziehe ich einen weiten Stopp von etwa 25% unregelmäßig zur Absicherung nach.
In diesem Marktumfeld würde ich aber selbst bei weitem Stopp auch schnell die Reißleine ziehen. Mir erging's bei Valence (Lithiumakkus) ähnlich wie Dir.
Insgesamt sehe ich bei QCOR noch 'ne Menge Potential. Es gibt ein mehr oder weniger konkurenzloses Produkt ACTHAR, das neben fröhlich sprudelnder Gewinne noch weitere Vermarktungsmöglichkeiten (IS) bietet (Studie ab 1.QT 2009 auch für NS und dafür gibt es noch gar kein zugelassenes Medikament!) und das weitere sich bereits im Markt befindendem Produkt DORAL, sowie weitere Produkte in der Pipeline. Und das bei einer MK von nur rund 500 Mio $...
Gruss
Hi Leute,
habe QUESTCOR gerade gegoogelt und auf diesen Link gestoßen
http://www.wallstreet-online.de/nachrichten/nachricht/260640…
Der Börsenbrief Global Biotech Investing hat auf unsere Perle am WE aufmerksam gemacht und ins Musterdepo genommen, vielleicht kommt hier jetzt noch mehr Schwung in die Kiste....was meint ihr?
Haendchen
habe QUESTCOR gerade gegoogelt und auf diesen Link gestoßen
http://www.wallstreet-online.de/nachrichten/nachricht/260640…
Der Börsenbrief Global Biotech Investing hat auf unsere Perle am WE aufmerksam gemacht und ins Musterdepo genommen, vielleicht kommt hier jetzt noch mehr Schwung in die Kiste....was meint ihr?
Haendchen
Wer auch immer noch dabei ist und vor allem diese heftigen Ausschläge mitgemacht hat. Auch heute wieder zwischen 6,50$ und 8,92$! Verrückt...
Ich wünsche allen ein entspanntes, erholsames und vor Allem erfolgreiches Jahr 2009!
Gruß
rohbi
Ich wünsche allen ein entspanntes, erholsames und vor Allem erfolgreiches Jahr 2009!
Gruß
rohbi
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -1,57 | |
| -0,11 | |
| +1,37 | |
| -0,34 | |
| -0,70 | |
| -0,98 | |
| +1,77 | |
| +3,28 | |
| +2,67 | |
| +2,19 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 120 | ||
| 82 | ||
| 60 | ||
| 57 | ||
| 41 | ||
| 30 | ||
| 26 | ||
| 25 | ||
| 24 | ||
| 23 |
